Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride

US7087613B2 · kind B2 · utility

Assignee

• OSI Pharmaceuticals, LLC · US

Inventors

• Timothy Norris · Gales Ferry, US
• Jeffrey W. Raggon · Uncasville, US
• Richard Connell · Trumbull, US
• James D. Moyer · Downingtown, US
• Michael John MORIN · Waterford, US
• Shama Kajiji · Mystic, US
• Barbara Foster · San Leandro, US
• Karen Ferrante · East Greenwich, US
• Sandra Leta Silberman · Dover, US

Key dates

• Filing date: Nov 18, 2004
• Grant date: Aug 8, 2006
• Expiry date: Nov 18, 2024

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method of monotherapy for a subject suffering from abnormal cell growth expressing the epidermal growth factor receptor (EGFR) which comprises orally administering to the subject a therapeutically effective amount of a crystalline polymorph of the hydrochloride salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine so as to treat the subject.